Effect of Atenolol on Hepatic Dysfunction by Evaluating Level of AST
Hepatic Dysfunction by Evaluating Level of AST
DOI:
https://doi.org/10.54393/pbmj.v6i06.885Keywords:
AST level, Hypertension, AtenololAbstract
Hypertension is one of the most important risk factors for morbidity and mortality around the world. Many drugs used to treat hypertension have several side effects. Atenolol used to control hypertension, is an anti-beta-adrenergic agent. It has found to significantly affect the hepatic functions. Objective: To study the effects of atenolol on hepatic dysfunction by measuring AST level in hypertensive patients, taking atenolol alone or in combination with other anti-hypertensive drugs. Methods: The variation in AST level was measured upon use of atenolol alone or in combination with other anti-hypertensive drugs. Out of total 80 patients, 43 were treated with atenolol alone, 37 with atenolol in combination with other anti-hypertensive drugs and 20 were healthy controls. Micro lab tests were used for measurement of AST level. Results: Significant results were found as atenolol cause increase in AST level. Other anti-hypertensive drugs did not affect the AST levels much and the increase in AST level was more significant in patients taking atenolol alone. Conclusions: Atenolol may have efficacy in controlling hypertension, but it causes disturbance in AST levels therefore any other drug in combination with atenolol is recommended to avoid AST variation and eventually hepatic dysfunctions. Further this study may be employed on large scale for strengthening the outcomes of this study
References
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. Jama. 2003 May; 289(19): 2560-71. doi: 10.1001/jama.289.19.2560. DOI: https://doi.org/10.1001/jama.289.19.2560
Havlik RJ, Garrison RJ, Feinleib M, Kannel WB, Castelli WP, Mcnamara PM. Blood pressure aggregation in families. American Journal of Epidemiology. 1979 Sep; 110(3): 304-12. doi: 10.1093/oxfordjournals.aje.a112815. DOI: https://doi.org/10.1093/oxfordjournals.aje.a112815
Hamet P, Pausova Z, Adarichev V, Adaricheva K, Tremblay J. Hypertension: genes and environment. Journal of Hypertension. 1998 Apr; 16(4): 397-418. doi: 10.1097/00004872-199816040-00001. DOI: https://doi.org/10.1097/00004872-199816040-00001
Somers VK, Dyken ME, Mark AL, Abboud FM. Sympathetic-nerve activity during sleep in normal subjects. New England Journal of Medicine. 1993 Feb; 328(5): 303-7. doi: 10.1056/NEJM199302043280502. DOI: https://doi.org/10.1056/NEJM199302043280502
Mark AL. The sympathetic nervous system in hypertension: a potential long-term regulator of arterial pressure. Journal of hypertension. Supplement: official Journal of the International Society of Hypertension. 1996 Dec; 14(5): S159-65.
Esler M. The sympathetic system and hypertension. American Journal of Hypertension. 2000 Jun; 13(S4): 99S-105S. doi: 10.1016/S0895-7061(00)00225-9. DOI: https://doi.org/10.1016/S0895-7061(00)00225-9
Messerli FH and Nussberger J. Vasopeptidase inhibition and angio-oedema. The Lancet. 2000 Aug; 356(9230): 608-9. doi: 10.1016/S0140-6736(00)02596-4. DOI: https://doi.org/10.1016/S0140-6736(00)02596-4
Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. Original Papers. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid‐lowering treatment to prevent heart attack trial (ALLHAT). The Journal of Clinical Hypertension. 2002 Nov;4(6):393-404. doi: 10.1111/j.1524-6175.2002.02045.x. DOI: https://doi.org/10.1111/j.1524-6175.2002.02045.x
Agon P, Goethals P, Van Haver D, KAUFMAN JM. Permeability of the blood‐brain barrier for atenolol studied by positron emission tomography. Journal of pharmacy and pharmacology. 1991 Aug; 43(8): 597-600. doi: 10.1111/j.2042-7158.1991.tb03545.x. DOI: https://doi.org/10.1111/j.2042-7158.1991.tb03545.x
Kulcsar-Gergely J, Posan E, Kulcsar A. Metabolic actions of a single atenolol and metoprolol dose. Arzneimittel-forschung. 1994 Nov; 44(11): 1183-5.
Gowda S, Desai PB, Hull VV, Avinash AK, Vernekar SN, Kulkarni SS. A review on laboratory liver function tests. The Pan African Medical Journal. 2009 Nov; 3: 17.
Zusman RM, Prisant LM, Brown MJ, Sildenafil Study Group. Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. Journal of Hypertension. 2000 Dec; 18(12): 1865-9. doi: 10.1097/00004872-200018120-00022. DOI: https://doi.org/10.1097/00004872-200018120-00022
Nyblom H, Berggren U, Balldin J, Olsson R. High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking. Alcohol and alcoholism. 2004 Jul; 39(4): 336-9. doi: 10.1093/alcalc/agh074. DOI: https://doi.org/10.1093/alcalc/agh074
Mondal MK, Nessa A, Khatun N. Study of Body Mass Index, Blood Pressure, Serum Sodium in Newly Diagnosed Hypertensive Patients. Mymensingh Medical Journal: MMJ. 2023 Apr; 32(2): 355-60.
Brunström M, Brunström A, Jussil H, Panagiotopoulou K, Chaimani A, Carlberg B. Comparative efficacy and acceptability of different antihypertensive drug classes for cardiovascular disease prevention: a systematic review and network meta-analysis. Journal of Hypertension. 2023 Jun; 41(1): e78-9. doi: 10.1097/01.hjh.0000939516.35507.91. DOI: https://doi.org/10.1097/01.hjh.0000939516.35507.91
Shan Y, Cheung L, Zhou Y, Huang Y, Huang RS. A systematic review on sex differences in adverse drug reactions related to psychotropic, cardiovascular, and analgesic medications. Frontiers in Pharmacology. 2023 May; 14: 1096366. doi: 10.3389/fphar.2023.1096366. DOI: https://doi.org/10.3389/fphar.2023.1096366
Jeeyavudeen MS, Khan SK, Fouda S, Pappachan JM. Management of metabolic-associated fatty liver disease: The diabetology perspective. World Journal of Gastroenterology. 2023 Jan; 29(1): 126. doi: 10.3748/wjg.v29.i1.126.
Dumortier J, Guillaud O, Gouraud A, Pittau G, Vial T, Boillot O, et al. Atenolol hepatotoxicity: report of a complicated case. Annals of Pharmacotherapy. 2009 Oct; 43(10): 1719-23. doi: 10.1345/aph.1M247. DOI: https://doi.org/10.1345/aph.1M247
Jeeyavudeen MS, Khan SK, Fouda S, Pappachan JM. Management of metabolic-associated fatty liver disease: The diabetology perspective. World Journal of Gastroenterology. 2023 Jan; 29(1): 126. doi: 10.3748/wjg.v29.i1.126. DOI: https://doi.org/10.3748/wjg.v29.i1.126
Hasan R, Javaid A, Fatima H, Safdar W. Alterations in plasma electrolytes and serum liver enzymes induced by atenolol in common rabbits Oryctolagus cuniculus. Pakistan Journal of Biological Science. 2006 Dec; 9(12): 2342-3. doi: 10.3923/pjbs.2006.2342.2345. DOI: https://doi.org/10.3923/pjbs.2006.2342.2345
Amin EA, Hassan SA, Ali ST. Relationship between atenolol and early development of heart failure in hypertensive patients. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2009 Jun; 6(1): 107-15. doi: 10.32947/ajps.v6i1.364. DOI: https://doi.org/10.32947/ajps.v6i1.364
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Pakistan BioMedical Journal
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments editor@pakistanbmj.com